Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295559178> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4295559178 endingPage "1523" @default.
- W4295559178 startingPage "1523" @default.
- W4295559178 abstract "To measure the association between intravenous administration of monoclonal antibody bamlanivimab (LY-CoV555) to long-term care facility (LTCF) residents recently diagnosed with pre-symptomatic, mild-to-moderate COVID-19 and are considered high risk for disease progression with mortality, hospitalization, and adverse effects. A retrospective analysis of LTCF residents with confirmed COVID-19, pre-symptomatic, mild to moderate disease, who were treated with bamlanivimab (LY-CoV555) were compared to similar LTCF residents who did not receive monoclonal antibody treatment. Dependent variables investigated included mortality and hospitalization as primary outcomes with adverse effects as the secondary outcome. A total of 107 residents from three LTCFs were diagnosed with pre-symptomatic, mild-to-moderate COVID-19 between November 1, 2020, and December 31, 2020. Of the 107 study participants, 44 residents provided consent to treatment, of which 39 received a single intravenous infusion of neutralizing monoclonal antibody, bamlanivimab 700mg, early in the disease, and 5 received an incomplete dose. Of the 39 residents who received the full dose of bamlanivimab, 5 (12.8%) were admitted to the hospital and 4 (10.3%) died. Conversely, of the 63 residents who did not receive the monoclonal antibody, 26 (41.3 %) were admitted to the hospital and 18 (28.6%) died. Relative risk for hospitalization and death were statistically significantly lower for those residents who received the full bamlanivimab treatment. No serious adverse effects were documented on any patient. Intravenous administration of monoclonal antibody bamlanivimab (LY-CoV555) to LTCF residents recently diagnosed with pre-symptomatic, mild to moderate COVID-19 was significantly associated with reduced mortality and hospitalization. The monoclonal antibody was well-tolerated." @default.
- W4295559178 created "2022-09-14" @default.
- W4295559178 creator A5016448983 @default.
- W4295559178 creator A5021869782 @default.
- W4295559178 creator A5029270336 @default.
- W4295559178 creator A5031190652 @default.
- W4295559178 creator A5048427768 @default.
- W4295559178 creator A5084192379 @default.
- W4295559178 date "2022-01-01" @default.
- W4295559178 modified "2023-09-27" @default.
- W4295559178 title "Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents" @default.
- W4295559178 cites W3009885589 @default.
- W4295559178 cites W3043192034 @default.
- W4295559178 cites W3092503590 @default.
- W4295559178 cites W3096658347 @default.
- W4295559178 cites W3164832774 @default.
- W4295559178 cites W3187723563 @default.
- W4295559178 cites W3202074923 @default.
- W4295559178 doi "https://doi.org/10.14336/ad.2022.0205" @default.
- W4295559178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36186125" @default.
- W4295559178 hasPublicationYear "2022" @default.
- W4295559178 type Work @default.
- W4295559178 citedByCount "2" @default.
- W4295559178 countsByYear W42955591782022 @default.
- W4295559178 countsByYear W42955591782023 @default.
- W4295559178 crossrefType "journal-article" @default.
- W4295559178 hasAuthorship W4295559178A5016448983 @default.
- W4295559178 hasAuthorship W4295559178A5021869782 @default.
- W4295559178 hasAuthorship W4295559178A5029270336 @default.
- W4295559178 hasAuthorship W4295559178A5031190652 @default.
- W4295559178 hasAuthorship W4295559178A5048427768 @default.
- W4295559178 hasAuthorship W4295559178A5084192379 @default.
- W4295559178 hasBestOaLocation W42955591781 @default.
- W4295559178 hasConcept C126322002 @default.
- W4295559178 hasConcept C159654299 @default.
- W4295559178 hasConcept C167135981 @default.
- W4295559178 hasConcept C187212893 @default.
- W4295559178 hasConcept C194828623 @default.
- W4295559178 hasConcept C197934379 @default.
- W4295559178 hasConcept C203014093 @default.
- W4295559178 hasConcept C2779134260 @default.
- W4295559178 hasConcept C3008058167 @default.
- W4295559178 hasConcept C524204448 @default.
- W4295559178 hasConcept C542903549 @default.
- W4295559178 hasConcept C71924100 @default.
- W4295559178 hasConceptScore W4295559178C126322002 @default.
- W4295559178 hasConceptScore W4295559178C159654299 @default.
- W4295559178 hasConceptScore W4295559178C167135981 @default.
- W4295559178 hasConceptScore W4295559178C187212893 @default.
- W4295559178 hasConceptScore W4295559178C194828623 @default.
- W4295559178 hasConceptScore W4295559178C197934379 @default.
- W4295559178 hasConceptScore W4295559178C203014093 @default.
- W4295559178 hasConceptScore W4295559178C2779134260 @default.
- W4295559178 hasConceptScore W4295559178C3008058167 @default.
- W4295559178 hasConceptScore W4295559178C524204448 @default.
- W4295559178 hasConceptScore W4295559178C542903549 @default.
- W4295559178 hasConceptScore W4295559178C71924100 @default.
- W4295559178 hasIssue "5" @default.
- W4295559178 hasLocation W42955591781 @default.
- W4295559178 hasLocation W42955591782 @default.
- W4295559178 hasLocation W42955591783 @default.
- W4295559178 hasOpenAccess W4295559178 @default.
- W4295559178 hasPrimaryLocation W42955591781 @default.
- W4295559178 hasRelatedWork W1969822711 @default.
- W4295559178 hasRelatedWork W1999686187 @default.
- W4295559178 hasRelatedWork W2019666956 @default.
- W4295559178 hasRelatedWork W2049834980 @default.
- W4295559178 hasRelatedWork W2073840950 @default.
- W4295559178 hasRelatedWork W2340284051 @default.
- W4295559178 hasRelatedWork W3013145321 @default.
- W4295559178 hasRelatedWork W3095549380 @default.
- W4295559178 hasRelatedWork W3208090289 @default.
- W4295559178 hasRelatedWork W3210359220 @default.
- W4295559178 hasVolume "13" @default.
- W4295559178 isParatext "false" @default.
- W4295559178 isRetracted "false" @default.
- W4295559178 workType "article" @default.